Komori
COSMOS Pharmaceutical (3349) · PolicyUpdated restricted stock compensation results

No Performance-Linked or Share-Based Compensation Initially, Followed by a制度 Review

First written in FY2020. 3 of 8 entries say "Advanced", first in FY2021. Latest entry: FY2026.

8entries
7years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021RestatedFY2022AdvancedFY2023 – FY2024-Q2OtherFY2025 – FY20262020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Medium- to Long-Term Incentives Through Equity Compensation Plans for Directors and EmployeesA theme 663 companies write about · 0 as a headwind · 686 as a tailwind

19 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.Comparing 200 of the theme's 686 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Updated restricted stock compensation resultsAnnual report

    「Directors (excluding Audit and Supervisory Committee members) (Excluding outside directors) 93 71 — 22 22 4」

    Under the restricted stock compensation system, the company recorded ¥22 million in share-based compensation expense for 4 Eligible Directors during the fiscal year.
  2. 2026-08-04RestatedGeneral Meetings of Shareholders

    「Executive compensation consists of fixed compensation based on roles and responsibilities, executive bonuses paid on an ad hoc basis, and restricted stock compensation intended to further increase directors' motivation to contribute to share-price appreciation and the enhancement of corporate value.」

    The Company disclosed the continuation of its restricted stock compensation system and ¥22 million in share-based compensation expense for the current fiscal year.
  3. FY2025Updated restricted stock compensation resultsAnnual report

    「Directors (excluding Audit and Supervisory Committee members) (Excluding outside directors) 93 70 — 22 22 3」

    Under the restricted stock compensation system, the company recorded ¥22 million in share-based compensation expense for 3 Eligible Directors during the fiscal year.
  4. FY2024-Q2AdvancedAnnual report

    「Based on the disposal of treasury shares as restricted stock compensation resolved at a meeting of the Board of Directors held on 22 August 2023, the company disposed of 30,000 treasury shares on 19 September 2023.」

    On 19 September 2023, the company disposed of 30,000 treasury shares as restricted stock compensation for directors and employees, implementing the system.
  5. FY2023AdvancedAnnual report

    「This system is being introduced as a share-based compensation system under which restricted stock will be granted to the company's directors, excluding directors who are Audit and Supervisory Committee members and outside directors (hereinafter, the "Eligible Directors"), so that the Eligible Directors share with shareholders the benefits and risks of fluctuations in the share price and have a greater incentive than before to contribute to increasing the share price and enhancing corporate value.」

    The introduction of a restricted stock compensation system was approved at the General Meeting of Shareholders as share-based compensation that had not previously been introduced. The annual limit on monetary compensation claims was set at ¥900 million, and the annual allocation limit at 30,000 shares.
  6. FY2022RestatedAnnual report

    「To ensure objectivity and transparency in procedures for determining executive compensation and other remuneration, the company has established a Nomination and Compensation Committee chaired by an internal director, with independent outside directors comprising a majority of its members.」

    While performance-linked compensation and share-based compensation have not been introduced as of the present time, the company continues to determine compensation through a Nomination and Compensation Committee in which independent outside directors constitute a majority.
  7. FY2021AdvancedAnnual report

    「To ensure objectivity and transparency in procedures for determining executive compensation and other remuneration, the company has established a Nomination and Compensation Committee chaired by an internal director, with independent outside directors comprising a majority of its members.」

    Although performance-linked compensation and share-based compensation have not yet been introduced, the company specified the establishment of a Nomination and Compensation Committee with a majority of independent outside directors as a mechanism for ensuring objectivity and transparency in compensation decisions.
  8. FY2020First statedAnnual report

    「Performance-linked compensation and share-based compensation have not been introduced at this time. Going forward, we will consider a better compensation system incorporating objective and transparent procedures so that each director can fully perform his or her role in enhancing corporate value.」

    The company explained that executive compensation consists of fixed compensation and nonrecurring bonuses for directors, and that performance-linked compensation and share-based compensation have not been introduced. It stated that it would consider a compensation system with greater objectivity and transparency going forward.
Moved together

"Further Growth Through Proactive Store Expansion" moved the same way as this thread, in the same document, in 3 of its 8 moves.

33332★12345
  1. ★This thread
  2. 1Further Growth Through Proactive Store Expansion3×
  3. 2Achieving a Dominant Share in Western Japan3×
  4. 3New Store Openings and Expansion of the Store Network3×
  5. 4Continued Capital Investment in New Stores3×
  6. 5Generating Earnings by Strengthening Initiatives Involving Value-Added Products2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet. It last moved in the General Meetings of Shareholders of 2026-08-04: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
No Performance-Linked or Share-Based Compensation Initially, Followed by a制度 Review | COSMOS Pharmaceutical Corporation (3349) | Komori